CNS Pharmaceuticals doses first group of patients to treat recurrent GBM in 'big moment'

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO John Climaco tells Proactive the Houston, Texas-based biopharmaceutical company has dosed its first patients in its clinical trial to treat recurrent glioblastoma multiforme (GBM), an aggressive type of brain cancer.

Climaco says based on its Phase 1 data, he’s hopeful the group will see ‘activity’ within patients. He adds further patient enrollment is going well, as it lines up clinical sites around the world.